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Abstract. Type VI collagen (COL6), an extracellular matrix 
protein, is important in maintaining the integrity of lung 
tissue. An increase in COL6 mRNA and protein deposition 
was found in the lungs of patients with pulmonary fibrosis, a 
chronic inflammatory condition with a strong association with 
lung cancer. In the present study, we demonstrated overexpres-
sion of COL6 in the lungs of non-small cell lung cancers. We 
hypothesized that excessive COL6 in the lung interstitium 
may exert stimulatory effects on the adjacent cells. In vitro 
stimulation of monocytes with COL6 resulted in the produc-
tion of IL-23, which may promote tumor development in an 
environment of IL-23-mediated lung inflammation, where 
tissue modeling occurs concurrently with excessive COL6 
production. In addition, COL6 was capable of stimulating 
signaling pathways that activate focal adhesion kinase and 
extracellular signal-regulated kinase 1/2 in lung epithelial 
cells, which may also facilitate the development of lung 
neoplasms. Taken together, our data suggest the potential role 
of COL6 in promoting lung neoplasia in diseased lungs where 
COL6 is overexpressed.
Introduction
Extracellular matrix (ECM) proteins provide structural support 
for lung cells involved in gas exchange and may also actively 
regulate various aspects of lung function in both homeostatic 
and pathological conditions. Persistent exposure to cigarette 
smoke or airborne pollutants leads to the recruitment and acti-
vation of monocytes and alveolar macrophages (1,2). These, 
in turn release proteases that destroy ECM components in the 
alveolar septa, resulting in the development of emphysema, a 
common type of chronic obstructive pulmonary disease (3). On 
the other hand, increased degradation of ECM may promote 
aberrant remodeling of the connective tissues with resultant 
lung fibrosis. Lung fibrosis and emphysema may coexist 
and indeed, expression of a large number of ECM-related 
genes are upregulated in the lungs of smokers with severe 
emphysema (4,5). Among increased ECM proteins, type VI 
collagen (COL6) is deposited early in lung fibrosis (6). Both 
emphysema and lung fibrosis have a strong association with 
the occurrence of lung cancers (7-9). However, the expression 
patterns of COL6 in human lung cancers are largely unknown.
Collagen, an ECM protein, is important in maintaining the 
integrity of the lung tissues (10). The pulmonary interstitial 
compartment provides the scaffold and connection to the 
alveolar network via the contents of matrix proteins. Although 
COL6 is not the major structural element of the lung, it is 
present in the interstitium of the lung (10), as fine microfibrils 
with 3-10 nm in diameter that exhibit a double-beaded period 
of ~100 nm (11). COL6 consists of monomers containing at 
least 3 major polypeptides, α1, α2 and α3. The monomers 
aggregate intracellularly into dimers and then tetramers (12). 
Three additional polypeptides (α4, α5 and α6) have been iden-
tified to have high homology to the α3 chain (13,14).
The multi-domain structure of COL6 allows its inter-
action with components of matrix, including biglycan, 
decorin (15,16), hyaluronic acid (17), heparin sulphate (18) and 
type I (COL1) and type IV (COL4) collagen (6,19,20). Such 
interaction can stabilize ECM architecture, which is important 
in maintaining the integrity of tissues in the lung (10). In addi-
tion to the matrix-interaction, COL6 binds to integrins (21) of 
various cell types, initiating the matrix-cell interaction and 
affecting signaling pathways that regulate cellular functions, 
such as proliferation (22), migration (23), differentiation (24) 
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and survival (25). COL6 has potent growth-stimulatory 
effects, which is associated with aggressive tumor growth (22). 
Increased expression of COL6 has also been positively corre-
lated with tumorigenesis (26-29).
In this report, we revealed increased levels of COL6 in the 
lung tissues of patients with non-small cell lung cancers. Since 
COL6 is located in the pulmonary interstitial compartment 
where it encounters various cell types, including infiltrated 
monocytes and epithelial cells, we hypothesized that excessive 
COL6 may have effects on its surrounding cells. the objective 
of this study was to understand the role of excessive COL6 in 
the lung tissues with aforementioned lung diseases. Our results 
demonstrated the stimulatory properties of COL6 on various 
cell types, which in turn may have impacts on the development 
of lung neoplasia from emphysematous or fibrotic lungs where 
COL6 is upregulated.
Materials and methods
Collagens, antibodies and other reagents. Human collagen 
type IV (COL4) and VI (COL6) purified chromatographically 
and immunologically from human placenta were obtained 
from Rockland Immunochemicals Inc. (Gilbertsville, Pa, 
Usa). human anti-COL6a1 polyclonal antibody for immu-
nohistochemical staining was obtained from santa Cruz 
Biotechnology (santa Cruz, Ca, Usa). Lipopolysaccharide 
(LPS from Escherichia coli 0111:B4) was from sigma-aldrich 
(St. Louis, MO, uSA).
Cell lines, human blood samples and primary cells. The 
human thP-1 monocytic cell line (atCC; american type 
Culture Collection, Manassas, Va, Usa; provided by Dr 
Michael Klemsz from Indiana university School of Medicine) 
was cultured in complete RPMI-1640 medium. human blood 
samples of healthy donors were obtained from the Indiana 
Blood Center. Peripheral blood mononuclear cells (PBMCs) 
were separated using Ficoll centrifugation and aliquots of 
PBMCs were cryopreserved in liquid nitrogen. human primary 
monocytes were isolated from PBMCs using CD14 magnetic 
beads with ~93% of purity (Miltenyi Biotec Inc., auburn, Ca, 
Usa). human bronchial epithelial cells (hBEpCs) derived 
from the surface epithelium of normal human bronchi were 
obtained from Cell applications (san Diego, Ca, Usa) and 
were cultured in Bronchial/tracheal Epithelial Cell Growth 
Medium provided by the same supplier.
Gene expression in normal and neoplastic lung tissues. Tissue 
scan Lung Cancer tissue qPCR Panel II containing 48 tissues 
covering 4 disease stages (Ia, IB, IIa, IIB, IIIa, IIIB and IV) 
of nsCLC and normal controls were obtained from OriGene 
Technologies (Rockville, MD, uSA). The gene expression of 
COL6A1 and IL23A was analyzed using the taqMan assay 
primers with ACTB (β-actin) as endogenous control in the 
aBI 7300 system (applied Biosystems by Life technologies, 
Carlsbad, Ca, Usa).
Analysis of COL6 protein in human lung tissues using 
immunohistochemistry staining. Lung disease tissue array 
slides (LuD481 and LuC962) containing normal controls, 
adenocarcinoma and squamous cell carcinoma were obtained 
from Us Biomax (Rockville, MD, Usa). the levels of COL6 
protein were analyzed using immunohistochemical staining 
with an anti-COL6a1 polyclonal antibody (santa Cruz 
Biotechnology).
Cytokine production by monocytes. Monocytes (2-4x106 
cells/ml) freshly purified from normal PBMCs were treated 
with medium only, LPS (1 µg/ml) and COL6 at the concen-
trations of 10 or 30 µg/ml. Eight hours following treatment, 
the supernatants were collected and the cell pellets were 
resuspended in tRIzol reagents (Invitrogen, Carlsbad, Ca, 
Usa) for total Rna extraction, first-strand cDna synthesis 
(Invitrogen) followed by real-time qPCR with taqMan assay 
primers for IL1B (IL-1β), IL6 (IL-6), TNFA (TNFα), IL23A 
(p19) and IL12B (p40). The levels of cytokine secretion in the 
supernatants, including IL-23 and TNFα were measured using 
ELIsa as previously described (30).
Analysis of focal adhension kinase (FAK) and extracellular 
signal-regulated kinase (ERK) activation following stimula-
tion. thP-1 or hBEpC cells were stimulated as indicated 
at 37˚C in a 5% CO2 incubator for 1 h. Cells were lysed 
using the RIPa protein lysis buffer consisting of 10% glyc-
erol, 1% Igepal, 50 mM tris-ph 7.4, 150 mM naCl, 1 mM 
EDta-ph 8.0, 1% na-deoxycholate, 0.1% sDs and protease 
inhibitors (31). activation of FaK was evaluated using 
western blot analysis with antibodies against phospho-FaK 
(P-FaK) at tyr 397 (Y397) and Y925 followed by total FaK 
(Cell Signaling Technology, Danvers, MA, uSA). Activation 
of ERK1/2 was evaluated using western blot analysis with 
phospho-P44/42 ERK1/2 (thr202/tyr204) followed by total 
ERK antibodies (Cell signaling technology). the band 
intensity was determined using Image J program (NIH) and 
the ratios were calculated as the intensity of phosphorylated 
proteins divided by the intensity of total proteins.
Statistical analysis. PasW statistics (IBM-sPss, Chicago, IL, 
uSA) was used to analyze the data. P-value was determined 
with an independent Student's t-test.
Results
COL6 expression is upregulated in neoplastic lung tissues. 
In this study, we evaluated the levels of COL6 in neoplastic 
lung tissues. The gene expression of COL6A1 was signifi-
cantly higher in lung tissues with NSCLC at various stages, 
as compared to that from normal controls (Fig. 1A). In addi-
tion, the levels of COL6 protein were elevated in lung tissues 
from nsCLC patients with adenocarcinoma and squamous 
cell carcinoma (Fig. 1B and C). Positive staining for COL6a1 
was more intense in the cytoplasm of stromal cells and in the 
immediately adjacent extracellular space. uninvolved healthy 
lung tissue sections displayed the normal structure of alveoli, 
whereas lung adenocarcinoma sections exhibited various 
stages of neoplastic differentiation with loss of normal alveolar 
structures (Fig. 1B). a marked staining of COL6 was noted 
in 65% (15/23) of the lung tissues from the nsCLC patients 
analyzed (Fig. 1C). We found no significant difference in 
COL6 staining from the lung tissues among the three different 
grades (grade 1-3) of lung cancer (Fig. 1B and C).
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COL6 stimulates monocytes to produce IL-23. During lung 
inflammation, lung epithelial cells are activated upon exposure 
to irritants and produce chemokines that attract immune cells 
from the periphery to the lungs. Among these chemokines, 
CCL2 attracts CCR2-expressing monocytes (32). Given 
the fact that elevation of COL6 is present in the pulmonary 
Figure 1. Expression of COL6 in normal and neoplastic lung tissues. (A) COL6A1 gene expression in human lung tissues. TissueScan Lung Cancer Tissue 
qPCR Panel II containing 48 tissues covering 4 disease stages (Ia, IB, IIa, IIB, IIIa, IIIB and IV) of nsCLC and normal tissues (n) was used. the gene 
expression level of COL6A1 was analyzed using taqMan assay primers with ACTB (β-actin) as endogenous control. Data are presented as mean ± SD in a 
bar graph from each group. Open circle (○) indicates the expression level of individual tissue from the group. P-value is compared to the normal tissues. (B) 
Immunohistochemical staining of COL6 protein from human lung tissues. Lung disease tissue array slides (LuD481 and LuC962) containing normal controls 
and NSCLC (grade 1-3) were used. The levels of COL6 protein in the slides were analyzed using immunohistochemical staining with anti-COL6A1 polyclonal 
antibody. Representative image of adenocarcinoma (grade 1-3) and normal lung at higher magnification (x200) is shown from slide LUD481. (C) Intensity 
of COL6A1 staining in the whole tissues in the slides was analyzed using Image J program and presented as the mean intensity ± SD from normal (n=6) and 
nsCLC (n=23; total grade 1-3), including grade 1 (n=7; 3 adenocarcinoma and 4 squamous cell carcinoma), grade 2 (n=8; 3 adenocarcinoma and 5 squamous 
cell carcinoma), grade 3 (n=8; 3 adenocarcinoma and 5 squamous cell carcinoma). P-value is compared to the normal tissues. COL6, type VI collagen; nsCLC, 
non-small cell lung cancer.
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interstitium, an area shared with recruited monocytes during 
lung inflammation, we first tested the hypothesis that excessive 
COL6 has stimulatory effects on monocytes. To investigate 
whether monocytes respond to COL6, human primary mono-
cytes were purified from PBMCs of normal control donors 
using CD14+ magnetic microbeads with a purity of ~93%. 
Isolated monocytes were stimulated with different concentra-
tions of COL6 followed by analysis of cytokine production.
Human monocytes express toll-like receptor 4 that responds 
to LPs stimulation, resulting in induction of pro-inflammatory 
cytokines (33). LPS was therefore used as a positive control 
in the in vitro study. As expected, LPS stimulation in human 
monocytes resulted in upregulation of pro-inflammatory 
cytokines such as IL1B, IL6 and TNFA (Fig. 2A). We found 
that COL6 stimulation had no significant effects on expression 
of IL1B, IL6 and TNFA (Fig. 2A). However, increased gene 
expression of each subunit (IL23A for p19 and IL12B for p40) 
of IL-23 was noted following LPS or COL6 stimulation in the 
monocytes (Fig. 2B, upper panel). In addition, production of 
IL-23 was dependent on the dose of COL6 as no detectable 
level of secreted IL-23 was noticed using a lower concentration 
of COL6 (Fig. 2B, lower panel). similar to TNFA gene expres-
sion, secreted TNFα was only detected following stimulation 
with LPs, but not with medium or COL6 (Fig. 2C).
Figure 2. COL6 stimulates human monocytes to produce IL-23. human primary monocytes were isolated from peripheral blood mononuclear cells (PBMCs) 
of normal control donors using CD14 magnetic microbeads. Isolated monocytes were stimulated with medium only (-), lipopolysaccharide (LPs, 1 µg/ml) and 
different concentrations of type VI collagen (COL6) for 8 h. The cell pellets collected following 8 h of stimulation were analyzed for gene expression using 
qPCR with taqMan assay primers for IL1B, IL6, TNFA (A), IL23A and IL12B (B, upper panel). the levels of IL-23 (p19+p40) (B, lower panel) and tnFα (C) 
in the supernatants were determined using ELISA. Results are presented as mean ± SD averaged from 3 different donors. *P≤0.05, ***P≤0.001, relative to cells 
cultured in medium (-).
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IL23A expression is upregulated in neoplastic lung tissues. 
IL-23 has been implicated in the development of cancers (34). 
the induction of IL-23 by monocytes following COL6 stimu-
lation prompted us to examine whether the levels of IL-23 
were elevated in the lung tissues of patients with NSCLC. 
The expression of IL23A encoding the p19 subunit of IL-23 
was examined from another duplicate lung cancer tissue panel 
as in Fig. 1A. Elevated gene expression of IL23A was found 
in lung tissues of NSCLC as compared to that from normal 
controls (Fig. 3a, left panel). this profile was similar to that of 
COL6A1 expression (Fig. 3A, right panel). However, the tissue 
with higher COL6A1 expression was not always correlated 
with higher IL23A levels (Fig. 3A). Despite the individual 
variation and sample sizes, IL23A expression was significantly 
higher at various stages (IIa, IIB, IIIa and IV) of nsCLC 
than that of normal controls (Fig. 3B).
COL6 activates the FAK signaling pathway in monocytes. 
Monocytes express integrins of the β1, β2, β3 and β5 subfami-
lies (35). Upon binding to its ligands, integrin stimulates the 
activation of FaK outside-in signaling, which contributes to 
various biological functions including cytokine production, 
cell proliferation, survival and differentiation (36). FAK acts as 
a scaffolding molecule for assembly of the other kinases upon 
integrin ligation. activation of FaK by integrin clustering leads 
to autophosphorylation at tyrosine (Y)397, which is a binding 
site for the Src homology 2 (SH2) domain of the Src-protein 
tyrosine kinases. Recruitment of Src family kinases results 
in the phosphorylation of Y925 in the C-terminal region of 
FAK (37,38).
Integrin is one of the receptors for COL6 (21). To test 
whether the integrin-FAK signaling pathway was activated in 
monocytes upon COL6 stimulation, human THP-1 monocytes 
were stimulated followed by analysis of FaK activation using 
western blot analysis (Fig. 4a). COL4 known to activate FaK 
in intestinal epithelial cells (39) was included in the stimula-
tion for comparison. We found that FAK was phosphorylated 
at Y397 and Y925 in THP-1 monocytes stimulated with COL6, 
Figure 3. Gene expression of IL23A in normal and neoplastic lung tissues. an identical set of tissuescan Lung Cancer tissue qPCR Panel II (as in Fig. 1) was 
analyzed for IL23A gene expression using taqMan assay primers with ACTB (β-actin) as endogenous control (aBI). (a) Each bar graph represents the expres-
sion level of IL23A (left panel) or COL6A1 (right panel) from individual samples covering 4 disease stages (Ia, IB, IIa, IIB, IIIa, IIIB and IV) of non-small 
cell lung cancer and normal tissues (n). (B) the level of IL23A expression is presented as mean ± sD in a bar graph from each group. P-value is compared to 
the normal tissues.
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suggesting the activation of FAK and Src upon COL6 stimula-
tion. In contrast, COL4 had little if any effects on P-FAK in 
the monocytes.
COL6 activates FAK signaling in lung epithelial cells. 
signaling through FaK activation has been implicated in the 
tumorigenic properties of lung cancer cells (40,41). Having 
shown the activation of FAK in monocytes, we next tested 
if COL6 was able to stimulate lung epithelial cells that also 
express integrin. Phosphorylation of FAK at Y925 was not 
detected from human primary epithelial cells cultured in 
medium only, while stimulation with COL6 in human primary 
epithelial cells resulted in an ~4-fold increase in phosphory-
lation of FAK at Y925 relative to those cultured in medium 
only. COL4 is known to activate FAK in intestinal epithelial 
cells (39) and we also observed an intermediate increase 
(~3-fold) in P-FAK (Y925) upon stimulation with COL4 in 
lung epithelial cells relative to the control (Fig. 4B).
COL6 activates MAPK/ERK signaling in lung epithelial cells. 
It is known that phosphorylation of FAK at Y925 creates a 
binding site for the growth factor-receptor-bound protein 2 
(GRB2) and activates a small G protein, Ras (37). activated 
RAS recruits mitogen-activated protein kinase kinase 
kinase (MAPKKK or RAF), which leads to activation of 
mitogen-activated protein kinase kinase (MAPKK or MEK), 
which then activates the mitogen-activated protein kinase 
(MAPK) extracellular signal-regulated kinase (ERK)1/2 (42). 
To further investigate the involvement of ERK1/2 in FAK 
signaling following COL6 stimulation, we examined the 
activation of ERK1/2 using western blot analysis. We found 
that human primary epithelial cells increased the levels of 
phosphorylation of ERK1/2 upon treatment of COL6 and an 
intermediate increase in ERK1/2 phosphorylation was also 
induced by COL4 (Fig.5).
Discussion
In the present study, we demonstrated that elevated gene 
expression of COL6A1 was present in the lungs with NSCLC 
at various stages. Lung tissues with adenocarcinoma or 
squamous cell carcinoma were associated with deposition of 
more COL6 as compared to normal lungs. COL6 is known 
for its potent growth-stimulating effects on promoting tumor 
progression (22,26-29). Our results from in vitro cultures 
suggest a novel function of excess COL6 on stimulating IL-23 
production by monocytes. We also found upregulation of 
IL23A expression in neoplastic lung tissues at various stages, 
consistent with the reports that overexpression of IL23A was 
present in human tumor samples (34). IL-23 has been impli-
cated in the development of cancers by increasing neutrophil 
and inhibiting CD8+ t cell infiltration, thereby promoting 
tumor incidence and growth (34). Our results suggest a poten-
tial role of COL6 in promoting inflammation that is favorable 
for tumor development.
Figure 4. COL6 activates FAK in human THP-1 monocytes and primary 
epithelial cells. (A) COL6 activates FAK in THP-1 cells. Human THP-1 
monocytic cell line was stimulated at 1x106 cells/ml with medium only (-), 
COL4 (30 µg/ml) and COL6 (30 µg/ml) for 1 h. Activation of FAK was 
evaluated using western blot analysis with phospho-FaK (P-FaK) at tyr397 
(Y397) and P-FaK (Y925) followed by total FaK antibodies. the band 
intensity was determined using Image J program and the ratio was calculated 
from the intensity of P-FaK divided by the intensity of total FaK as shown at 
the bottom of each blot. (B) COL6 activates FaK in primary epithelial cells. 
hBEpCs derived from the surface epithelium of normal human bronchi were 
cultured in Bronchial/tracheal Epithelial Cell Growth Medium following the 
manufacturer's instruction. hBEpCs were stimulated at 1x106 cells/ml with 
medium only (-), COL4 (30 µg/ml) and COL6 (30 µg/ml) for 1 h. Activation 
of FaK was evaluated using western blot analysis with P-FaK (Y925) fol-
lowed by total FaK antibodies. the band intensity was determined using 
Image J program and the ratio was calculated from the intensity of P-FAK 
divided by the intensity of total FaK (P-FaK-Y925/total FaK). Data are 
representative of similar profiles from two independent experiments using 
different passages of cells. COL6, type VI collagen; FaK, focal adhension 
kinase; hBEpCs, human bronchial epithelial cells.
Figure 5. COL6 activates ERK1/2 in human primary epithelial cells. hBEpCs 
described in Fig. 4B were stimulated with medium only (-), COL4 (30 µg/
ml), and COL6 (30 µg/ml) for 1 h. Activation of ERK was evaluated using 
western blot analysis with phospho-p44/42 ERK1/2 (thr202/tyr204) fol-
lowed by total ERK1/2 antibodies. the band intensity was determined using 
Image J program and the ratio was calculated from the intensity of P-ERK1 
divided by the intensity of total ERK1 (shown on the top of the band) or 
P-ERK2 divided by total ERK2 (shown on the bottom of the band). Data are 
representative of similar profiles from two experiments using different pas-
sages of primary epithelial cells. COL6, type VI collagen; ERK, extracellular 
signal-regulated kinase; hBEpCs, human bronchial epithelial cells.
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although IL-23 was induced by monocytes using a soluble 
form of COL6 in a dose-dependent manner, it was less efficiently 
induced using plate-bound COL6 (data not shown). Instead, 
we found that plate-bound COL6 had effects on endothelial 
cells, which are also present in the pulmonary interstitium. 
Primary lung endothelial cells treated with plate-bound COL6 
had increased levels of cleaved caspase-3 (data not shown), 
suggesting the induction of apoptosis. In this study, we did not 
identify the specific fragments of COL6, which are required 
for induction of IL-23 expression by monocytes. It is likely 
that different forms of COL6 are able to stimulate various cell 
types in physiological conditions.
In order to exhibit stimulatory effects in the lungs, COL6 
needs to be secreted and exposed to its surrounding target 
cells. It is known that COL6 is mainly produced by fibro-
blasts (43,44) and other cell types such as adipocytes (29) 
or macrophages are capable of expressing COL6 (45). It has 
been shown that tGF-β1 and TGF-β3 are responsible for 
increasing extracellular matrix expression by human lung 
fibroblasts (46). In addition, COL6 expression is induced by 
human macrophages following stimulation with IL-4, IL-10, 
or IL-13, which are involved in T helper type 2 (Th2) allergic 
inflammation (45). therefore, the existing inflammatory envi-
ronment especially mediated by th2 immunity may increase 
the expression of COL6 in the lung tissues.
another possible mechanism for upregulation of COL6A1 
gene expression is due to DNA hypomethylation in stromal 
cells under hypoxic conditions. It has been shown that a global 
genomic hypomethylation occurs in synovial fibroblasts from 
rheumatoid arthritis patients (47). Our preliminary data also 
found a greatly reduced DNA methylation in the COL6A1 
gene from lung tissue with both emphysema and adenocarci-
noma as compared to that of adjacent normal section from the 
same patient (data not shown). A hypoxic lung environment as 
in emphysema or lung fibrosis is likely to modulate expression 
of an array of genes such as ECM component COL6.
To determine if COL6 was increased during the 
early phases of emphysema, a mouse model of cigarette 
smoke-induced emphysema was established. Destruction of 
alveolar septa was evident in mice exposed to cigarette smoke 
for 4 months (data not shown). However, there was no evidence 
of increased Col6a1 transcription or protein deposition in the 
lung tissues during this phase of cigarette-induced lung injury 
characterized by lung tissue loss, but no neoplasia (data not 
shown). These results suggest destruction of ECM alone may 
not be sufficient to enhance COL6 expression and transform 
the cells. It is possible this occurs in the faulty repair phase 
of lung injury, since increased degradation of the ECM leads 
to aberrant remodeling of the connective tissues and excess 
matrix protein deposition leads to pulmonary fibrosis, which 
is sometimes present in the emphysematous lungs. Combined 
pulmonary fibrosis and emphysema (CPFE) is a recently 
recognized distinct condition in which the lung is prominently 
affected by both emphysema and lung fibrosis (48). CPFE 
may be even more strongly associated with lung cancer than 
either emphysema or lung fibrosis alone (49). Future investi-
gations will have to mechanistically evaluate whether or not 
overexpression of COL6 is critical to or it is merely associated 
with the progression of emphysema or lung fibrosis to lung 
neoplasm.
In this study, we showed that COL6 exerted its stimulatory 
effects involving the signaling pathway that activated FAK 
molecules in monocytes and epithelial cells. MAPK/ERK, 
the downstream molecule of FAK, was also activated in lung 
epithelial cells following COL6 stimulation. ERK is known 
to promote cell proliferation, angiogenesis, cell differentiation 
and cell survival, which contributes to the development of 
various types of cancers including NSCLC (31). In addition 
to promote IL-23-mediated lung inflammation by targeting 
monocytes, COL6 was capable of activating signaling 
molecules (e.g., FAK and ERK) in normal lung epithelial cells, 
which may promote the development of lung cancer. Inhibition 
of FaK has been beneficial on retardation of tumor progres-
sion (38). studies using small-molecule FaK inhibitor are 
currently in clinical trials for patients with various types of 
tumors (50). FaK is a relevant target in the inhibition of tumor 
progression as well as abrogation of COL6-mediated activity 
during tissue remodeling.
Destruction of ECM in the lung is regarded as the patho-
logical hallmark of emphysema. Although upregulation of 
COL6 is important for repairing the wounded tissues during 
the healing process, excess matrix protein deposition may lead 
to unwanted consequences, such as increased fibrosis, and/or 
as we postulate, increased tumorigenesis potential. In this 
report, we defined that COL6 exerted stimulatory effects on 
inducing IL-23 production by monocytes, supporting its role 
in activating immune cells to promote pro-tumor lung inflam-
mation during the process of tissue remodeling. Amelioration 
of the progression or abnormal reparative phases of emphy-
sema or lung fibrosis by blocking signaling pathways exerted 
by excessive ECM components such as COL6, may be an 
important step in inhibiting tumorigenesis.
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